Cadrenal Therapeutics (NASDAQ:CVKD) CEO Quang Pham Sells 3,898 Shares

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) CEO Quang Pham sold 3,898 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $4.41, for a total value of $17,190.18. Following the transaction, the chief executive officer directly owned 175,288 shares of the company’s stock, valued at $773,020.08. This trade represents a 2.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Cadrenal Therapeutics Stock Up 3.0%

Shares of NASDAQ:CVKD traded up $0.13 during trading on Friday, hitting $4.44. 58,936 shares of the company traded hands, compared to its average volume of 55,464. The stock has a market capitalization of $12.74 million, a price-to-earnings ratio of -0.79 and a beta of 1.59. The business’s fifty day moving average is $5.15 and its 200-day moving average is $6.93. Cadrenal Therapeutics, Inc. has a one year low of $4.14 and a one year high of $15.99.

Cadrenal Therapeutics (NASDAQ:CVKD) last posted its earnings results on Thursday, May 7th. The company reported ($1.04) EPS for the quarter, beating the consensus estimate of ($1.51) by $0.47. On average, analysts forecast that Cadrenal Therapeutics, Inc. will post -5.52 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Wall Street Zen upgraded Cadrenal Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th. HC Wainwright reduced their price objective on Cadrenal Therapeutics from $32.00 to $13.00 and set a “buy” rating for the company in a research report on Tuesday, April 7th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cadrenal Therapeutics in a research report on Monday, April 20th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $13.00.

Institutional Investors Weigh In On Cadrenal Therapeutics

A number of institutional investors have recently added to or reduced their stakes in CVKD. JPMorgan Chase & Co. acquired a new stake in Cadrenal Therapeutics in the third quarter worth approximately $103,000. Citadel Advisors LLC acquired a new stake in Cadrenal Therapeutics in the third quarter worth approximately $274,000. Geode Capital Management LLC lifted its position in Cadrenal Therapeutics by 14.3% in the fourth quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock worth $98,000 after purchasing an additional 1,818 shares during the period. Finally, DRW Securities LLC acquired a new stake in Cadrenal Therapeutics in the fourth quarter worth approximately $171,000. 7.92% of the stock is currently owned by institutional investors and hedge funds.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.